Search Site

Trends banner

Ozempic maker lowers outlook

The company posted tepid Q3 results.

Kimberly-Clark to buy Kenvue

The deal is valued at $48.7 billion.

BYD Q3 profit down 33%

This was a 33% year-on-year decrease.

Alphabet posts first $100 bn quarter

The growth was powered by cloud division buoyed by AI

Nvidia to take stake in Nokia

Nvidia share price soars 20%.

Sanofi 2022 net profit at $7.3bn

Sanofi's earnings per share rose by 17.1 percent to US$9 but Sanofi forecast low single-digit growth this year. (AFP)
  • Sanofi is aiming for US$10.9 billion in sales of Dupixent this year.
  • The company's net profit rose by eight percent in 2022.

PARIS, FRANCE – French pharmaceutical giant Sanofi forecast slower earnings growth for 2023 on Friday after profits jumped in 2022 on the back of popular eczema and asthma drug Dupixent.

The company’s net profit rose by eight percent to US$7.3 billion (6.7 billion euros) last year.

Its earnings per share, or profits divided by outstanding shares, rose by 17.1 percent to US$9 (8.26 euros), but Sanofi forecast “low single-digit” growth this year.

Sanofi shares fell following the announcement.

The company’s Dupixent treatment has been a huge success for Sanofi, raking in US$9 billion (8.3 billion euros) in sales last year.

“Dupixent and Vaccines continue to be our leading growth drivers,” Sanofi chief executive Paul Hudson said in a statement.

Sanofi is aiming for US$10.9 billion (10 billion euros) in sales of Dupixent this year.